Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling (original) (raw)

Nature volume 470, pages 548–553 (2011)Cite this article

This article has been updated

Abstract

Inflammatory mechanisms influence tumorigenesis and metastatic progression even in cancers whose aetiology does not involve pre-existing inflammation or infection, such as breast and prostate cancers1. For instance, prostate cancer metastasis is associated with the infiltration of lymphocytes into advanced tumours and the upregulation of two tumour-necrosis-factor family members: receptor activator of nuclear factor-κB (RANK) ligand (RANKL) and lymphotoxin2. But the source of RANKL and its role in metastasis have not been established. RANKL and its receptor RANK control the proliferation of mammary lobuloalveolar cells during pregnancy3 through inhibitor of nuclear factor-κB (IκB) kinase-α (IKK-α)4, a protein kinase that is needed for the self-renewal of mammary cancer progenitors5 and for prostate cancer metastasis2. We therefore examined whether RANKL, RANK and IKK-α are also involved in mammary/breast cancer metastasis. Indeed, RANK signalling in mammary carcinoma cells that overexpress the proto-oncogene Erbb2 (also known as Neu)6, which is frequently amplified in metastatic human breast cancers7,8, was important for pulmonary metastasis. Metastatic spread of _Erbb2_-transformed carcinoma cells also required CD4+CD25+ T cells, whose major pro-metastatic function was RANKL production. Most RANKL-producing T cells expressed forkhead box P3 (FOXP3), a transcription factor produced by regulatory T cells, and were located next to smooth muscle actin (SMA)+ stromal cells in mouse and human breast cancers. The dependence of pulmonary metastasis on T cells was replaceable by exogenous RANKL, which also stimulated pulmonary metastasis of RANK+ human breast cancer cells. These results are consistent with the adverse impact of tumour-infiltrating CD4+ or FOXP3+ T cells on human breast cancer prognosis9,10 and suggest that the targeting of RANKL–RANK can be used in conjunction with the therapeutic elimination of primary breast tumours to prevent recurrent metastatic disease.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Change history

A correction was made to the Acknowledgements.

References

  1. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010)
    Article CAS Google Scholar
  2. Luo, J. L. et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 446, 690–694 (2007)
    Article CAS ADS Google Scholar
  3. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000)
    Article CAS Google Scholar
  4. Cao, Y. et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763–775 (2001)
    Article CAS Google Scholar
  5. Cao, Y., Luo, J. L. & Karin, M. IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc. Natl Acad. Sci. USA 104, 15852–15857 (2007)
    Article CAS ADS Google Scholar
  6. Guy, C. T. et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl Acad. Sci. USA 89, 10578–10582 (1992)
    Article CAS ADS Google Scholar
  7. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989)
    Article CAS ADS Google Scholar
  8. Tiwari, R. K., Borgen, P. I., Wong, G. Y., Cordon-Cardo, C. & Osborne, M. P. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12, 419–425 (1992)
    CAS PubMed Google Scholar
  9. Bohling, S. D. & Allison, K. H. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod. Pathol. 21, 1527–1532 (2008)
    Article CAS Google Scholar
  10. Ohara, M. et al. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol. Immunother. 58, 441–447 (2009)
    Article CAS Google Scholar
  11. Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412–2424 (1999)
    Article CAS Google Scholar
  12. Body, J. J. et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J. Bone Miner. Res. 25, 440–446 (2010)
    Article CAS Google Scholar
  13. Fizazi, K. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564–1571 (2009)
    Article CAS Google Scholar
  14. Ercolini, A. M. et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med. 201, 1591–1602 (2005)
    Article CAS Google Scholar
  15. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540–3545 (1999)
    Article CAS ADS Google Scholar
  16. Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006)
    Article CAS ADS Google Scholar
  17. Kawai, T. et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 169, 987–998 (2006)
    Article CAS Google Scholar
  18. DeNardo, D. G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91–102 (2009)
    Article CAS Google Scholar
  19. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol. 4, 330–336 (2003)
    Article CAS Google Scholar
  20. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557–563 (2007)
    Article CAS ADS Google Scholar
  21. Luboshits, G. et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59, 4681–4687 (1999)
    CAS PubMed Google Scholar
  22. Gao, J. L. et al. Structure and functional expression of the human macrophage inflammatory protein 1α/RANTES receptor. J. Exp. Med. 177, 1421–1427 (1993)
    Article CAS Google Scholar
  23. Gobert, M. et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69, 2000–2009 (2009)
    Article CAS Google Scholar
  24. Bates, G. J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373–5380 (2006)
    Article Google Scholar
  25. Liao, D., Luo, Y., Markowitz, D., Xiang, R. & Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 4, e7965 (2009)
    Article ADS Google Scholar
  26. Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103–107 (2010)
    Article CAS ADS Google Scholar
  27. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102 (2010)
    Article CAS ADS Google Scholar

Download references

Acknowledgements

We thank L. Coussens for discussions and suggestions, V. Temkin and G. He for advice, and H. Herschman for critical reading. Work was supported by the National Institutes of Health (NIH). W.T. and W.Z. were supported by postdoctoral fellowships from Susan G. Komen for the Cure. A.S. was supported by NIH Asthma Research and Cancer Therapeutic training grants, and S.G. was supported by a research fellowship from the Crohn’s and Colitis Foundation of America. M.K. is an American Cancer Society research professor.

Author information

Author notes

  1. Wei Tan
    Present address: Present address: Pfizer Oncology Research Unit West, San Diego, California 92121, USA.,
  2. Wei Tan and Weizhou Zhang: These authors contributed equally to this work.

Authors and Affiliations

  1. Departments of Pharmacology and Pathology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, 9500 Gilman Drive, Mail Code 0723, La Jolla, California 92093, USA,
    Wei Tan, Weizhou Zhang, Amy Strasner, Sergei Grivennikov & Michael Karin
  2. Department of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, Florida, USA
    Jin Q. Cheng
  3. Department of Surgery, University of California San Diego, San Diego, 92103-8220, California, USA
    Robert M. Hoffman
  4. AntiCancer Inc., San Diego, 92111, California, USA
    Robert M. Hoffman

Authors

  1. Wei Tan
    You can also search for this author inPubMed Google Scholar
  2. Weizhou Zhang
    You can also search for this author inPubMed Google Scholar
  3. Amy Strasner
    You can also search for this author inPubMed Google Scholar
  4. Sergei Grivennikov
    You can also search for this author inPubMed Google Scholar
  5. Jin Q. Cheng
    You can also search for this author inPubMed Google Scholar
  6. Robert M. Hoffman
    You can also search for this author inPubMed Google Scholar
  7. Michael Karin
    You can also search for this author inPubMed Google Scholar

Contributions

W.T., W.Z., A.S. and M.K. designed the research. W.T., W. Z. and A.S. performed most of the experiments and analysed the data. W.T., W.Z., A.S. and M. K. wrote the manuscript. S.G. performed some of the experiments and analysed their data. J.Q.C. and R.M.H. provided essential reagents, in vivo imaging and technical discussions.

Corresponding author

Correspondence toMichael Karin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

The file contains Supplementary Figures 1-18 with legends, Supplementary Methods and additional references. (PDF 2729 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Tan, W., Zhang, W., Strasner, A. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling.Nature 470, 548–553 (2011). https://doi.org/10.1038/nature09707

Download citation

This article is cited by

Editorial Summary

Metastasis in breast cancer

In a mouse model of ErbB-driven mammary tumours, Tan et al. find a role for RANKL (receptor activator of nuclear factor-κB ligand) in the formation of lung metastases. RANKL is produced by regulatory T cells infiltrating the primary tumours, and acts through its receptor RANK, which is expressed on the cancer cells. Targeting RANKL may therefore prove useful in reducing breast cancer metastases.